206 related articles for article (PubMed ID: 26899408)
1. Identification of Novel BACE1 Inhibitors by Combination of Pharmacophore Modeling, Structure-Based Design and In Vitro Assay.
Ju Y; Li Z; Deng Y; Tong A; Zhou L; Luo Y
Curr Comput Aided Drug Des; 2016; 12(1):73-82. PubMed ID: 26899408
[TBL] [Abstract][Full Text] [Related]
2. Computational modelling of potent β-secretase (BACE1) inhibitors towards Alzheimer's disease treatment.
Ugbaja SC; Sanusi ZK; Appiah-Kubi P; Lawal MM; Kumalo HM
Biophys Chem; 2021 Mar; 270():106536. PubMed ID: 33387910
[TBL] [Abstract][Full Text] [Related]
3. Identification of new BACE1 inhibitors using Pharmacophore and Molecular dynamics simulations approach.
Dhanabalan AK; Kesherwani M; Velmurugan D; Gunasekaran K
J Mol Graph Model; 2017 Sep; 76():56-69. PubMed ID: 28710924
[TBL] [Abstract][Full Text] [Related]
4. Molecular docking based virtual screening of natural compounds as potential BACE1 inhibitors: 3D QSAR pharmacophore mapping and molecular dynamics analysis.
Kumar A; Roy S; Tripathi S; Sharma A
J Biomol Struct Dyn; 2016; 34(2):239-49. PubMed ID: 25707809
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and biological evaluation of quinazolinone-based hydrazones with potential use in Alzheimer's disease.
Haghighijoo Z; Firuzi O; Hemmateenejad B; Emami S; Edraki N; Miri R
Bioorg Chem; 2017 Oct; 74():126-133. PubMed ID: 28780149
[TBL] [Abstract][Full Text] [Related]
6. BACE1 molecular docking and anti-Alzheimer's disease activities of ginsenosides.
Choi RJ; Roy A; Jung HJ; Ali MY; Min BS; Park CH; Yokozawa T; Fan TP; Choi JS; Jung HA
J Ethnopharmacol; 2016 Aug; 190():219-30. PubMed ID: 27275774
[TBL] [Abstract][Full Text] [Related]
7. Identification of new BACE1 inhibitors for treating Alzheimer's disease.
Kushwaha P; Singh V; Somvanshi P; Bhardwaj T; Barreto GE; Ashraf GM; Mishra BN; Chundawat RS; Haque S
J Mol Model; 2021 Jan; 27(2):58. PubMed ID: 33517514
[TBL] [Abstract][Full Text] [Related]
8. Synthesis, in vitro biological evaluation and molecular docking studies of benzimidamides as potential BACE1 inhibitors.
Niu Y; Gao H; Xu F; Wang C; Liu P; Yang G; Sun Q; Xu P
Chem Biol Drug Des; 2012 Nov; 80(5):775-80. PubMed ID: 22882897
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and SAR analysis of potent BACE1 inhibitors: Possible lead drug candidates for Alzheimer's disease.
Tarazi H; Odeh RA; Al-Qawasmeh R; Yousef IA; Voelter W; Al-Tel TH
Eur J Med Chem; 2017 Jan; 125():1213-1224. PubMed ID: 27871037
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and structure-activity relationship study of multi-target triazine derivatives as innovative candidates for treatment of Alzheimer's disease.
Iraji A; Firuzi O; Khoshneviszadeh M; Nadri H; Edraki N; Miri R
Bioorg Chem; 2018 Apr; 77():223-235. PubMed ID: 29367079
[TBL] [Abstract][Full Text] [Related]
11. Design and synthesis of bicyclic acetals as Beta Secretase (BACE1) inhibitors.
Innocenti R; Lenci E; Menchi G; Pupi A; Trabocchi A
Bioorg Med Chem; 2017 Oct; 25(19):5077-5083. PubMed ID: 28359674
[TBL] [Abstract][Full Text] [Related]
12. Pharmacophore based 3D-QSAR modeling, virtual screening and docking for identification of potential inhibitors of β-secretase.
Palakurti R; Vadrevu R
Comput Biol Chem; 2017 Jun; 68():107-117. PubMed ID: 28288354
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of BACE1 for therapeutic use in Alzheimer's disease.
Luo X; Yan R
Int J Clin Exp Pathol; 2010 Jul; 3(6):618-28. PubMed ID: 20661410
[TBL] [Abstract][Full Text] [Related]
14. Hybrid structure-based virtual screening protocol for the identification of novel BACE1 inhibitors.
Vijayan RS; Prabu M; Mascarenhas NM; Ghoshal N
J Chem Inf Model; 2009 Mar; 49(3):647-57. PubMed ID: 19434899
[TBL] [Abstract][Full Text] [Related]
15. Polymethoxyflavones: Novel β-Secretase (BACE1) Inhibitors from Citrus Peels.
Youn K; Yu Y; Lee J; Jeong WS; Ho CT; Jun M
Nutrients; 2017 Sep; 9(9):. PubMed ID: 28869548
[TBL] [Abstract][Full Text] [Related]
16. Dynamic Simulation, Docking and DFT Studies Applied to a Set of Anti-Acetylcholinesterase Inhibitors in the enzyme β-Secretase (BACE-1): An Important Therapeutic Target in Alzheimer`s disease.
Silva-Junior EF; Barcellos Franca PH; Quintans-Junior LJ; Mendonca-Junior FJB; Scotti L; Scotti MT; de Aquino TM; de Araujo-Junior JX
Curr Comput Aided Drug Des; 2017 Nov; 13(4):266-274. PubMed ID: 28382866
[TBL] [Abstract][Full Text] [Related]
17. Structure-Based Survey of the Binding Modes of BACE1 Inhibitors.
Hu H; Chen Z; Xu X; Xu Y
ACS Chem Neurosci; 2019 Feb; 10(2):880-889. PubMed ID: 30540177
[TBL] [Abstract][Full Text] [Related]
18. Inhibitory activities of major anthraquinones and other constituents from Cassia obtusifolia against β-secretase and cholinesterases.
Jung HA; Ali MY; Jung HJ; Jeong HO; Chung HY; Choi JS
J Ethnopharmacol; 2016 Sep; 191():152-160. PubMed ID: 27321278
[TBL] [Abstract][Full Text] [Related]
19. β-secretase inhibitors for Alzheimer's disease: identification using pharmacoinformatics.
Islam MA; Pillay TS
J Biomol Struct Dyn; 2019 Feb; 37(2):503-522. PubMed ID: 29388503
[TBL] [Abstract][Full Text] [Related]
20. Novel pyrrolyl 2-aminopyridines as potent and selective human beta-secretase (BACE1) inhibitors.
Malamas MS; Barnes K; Hui Y; Johnson M; Lovering F; Condon J; Fobare W; Solvibile W; Turner J; Hu Y; Manas ES; Fan K; Olland A; Chopra R; Bard J; Pangalos MN; Reinhart P; Robichaud AJ
Bioorg Med Chem Lett; 2010 Apr; 20(7):2068-73. PubMed ID: 20223661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
